Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

December 1, 2021

Study Completion Date

December 16, 2022

Conditions

Binge-Eating DisorderObesity

Interventions

BEHAVIORAL

Cognitive-Behavioral Therapy (CBT)

CBT specialist treatment

DRUG

NB Medication (on-going from acute treatment)

Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)

Trial Locations (1)

Yale School of Medicine, New Haven

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER

NCT03063606 - Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment | Biotech Hunter | Biotech Hunter